CA-BEHAVIOSEC
31.5.2019 15:02:03 CEST | Business Wire | Press release
BehavioSec, the first vendor to pioneer behavioral biometrics, is attending Money20/20 Europe on June 3-5, 2019 in Amsterdam, Netherlands at the Amsterdam RAI. Money20/20 focuses on the mission of creating a simpler, fairer, faster and more inclusive financial system for individuals, businesses and society as a whole, bringing together more than 350 speakers to deliver the next frontier of Financial Services. BehavioSec CEO Neil Costigan will join the panel discussion, “The Changing Nature of Attacks and Attackers,” where he will discuss cybersecurity and risk management in an age where online commerce and trust are threatened by cybercrime threats continually bypassing traditional password authentication and anti-fraud measures.
Money20/20 attendees can visit BehavioSec at booth H92 throughout the event. BehavioSec will meet with customers and industry partners, brief media and analysts and present demos of the company’s Behavioral Biometrics Software Platform . Already in use with some of the biggest global brands in FinTech and financial services, BehavioSec’s software provides continuous online authentication of account holders by analyzing their unique physical behaviors, like typing patterns, cursor movements and touchscreen inputs.
“Traditional, one-time authentication measures like thumbprints and passwords can no longer protect and enable digital transformation in the financial services sector,” said Costigan. “With today’s constantly evolving attacks bypassing even once reliable multi-factor authentication methods, financial service organizations must find new ways to prevent fraud and cyber attacks without slowing down usability and functionality. Presenting at Money20/20 gives us the opportunity to show the success of behavioral biometrics in combating account takeover fraud in this new threat landscape.”
Join BehavioSec’s Neil Costigan at the following session:
|
What: |
The Changing Nature of Attacks and Attackers |
|
|
Who: |
Neil Costigan, CEO, BehavioSec (Speaker) | |
| Dr. Yinglian Xie, Co-Founder and CEO, DataVisor (Speaker) | ||
| Max Laemmle, Founder and CEO, Fraugster Limited (Speaker) | ||
| Andrew Jamieson, Technology & Security Director, UL (Moderator) | ||
|
When: |
Wednesday, June 5, 2019 from 14:10 p.m. to 14:50 p.m. CEST | |
|
Where: |
Industry Transmutation Stage at RAI Amsterdam, Amsterdam, Netherlands |
As CEO of BehavioSec, Costigan leads the company’s work delivering innovative behavioral biometric technology protecting consumer transactions, payments and financial firms from fraud and theft. He has more than 25 years’ of entrepreneurial and technical leadership experience in venture-backed startups, and global technology corporations spanning the U.S., and EU. A cryptographer by training, his career expanded to include software development, executive leadership and entrepreneurship. He holds an extensive portfolio of patents and serves as Principal Investigator for BehavioSec’s U.S. DOD DARPA projects.
Prior to BehavioSec, Costigan was VP for R&D at Smart Card manufacturer Gemplus (now Gemalto) and Co-founder/CTO at PKI specialists Celo Communications (Celo). Neil holds a PhD (2009) for his thesis on Elliptic Curve Cryptography on Modern Processor Architectures and has developed a number of commercial security applications. He frequently presents and presents on innovation, cryptography and network security.
Follow BehavioSec for more details and the latest in behavioral biometrics technology:
About BehavioSec
BehavioSec is the first vendor to pioneer behavioral biometrics. The company’s Behavioral Biometrics Platform is widely deployed across Global 2000 companies for its proven ability to dramatically reduce account fraud and data theft. Founded in 2008 out of groundbreaking academic research, BehavioSec technology allows companies to continuously verify digital identities with superior precision, in real-time. Strengthened with the leadership of serial entrepreneurs and experienced industry professionals, the BehavioSec team now spans the world, providing security while preserving a rich digital experience throughout web and mobile apps. BehavioSec is the only enterprise-grade vendor used in global deployments with some of the largest companies, reducing manual review whilst safeguarding millions of users and billions of transactions. BehavioSec investors include Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures and Octopus Ventures. BehavioSec is headquartered in San Francisco, CA and has global operations throughout Europe and Asia Pac. For more information, visit www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005032/en/
Contact:
Media Contact: Savannah Young +1 (703) 877-8111 pr@behaviosec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom